Skip to nav Skip to content

IDSA Media Briefing: FDA Emergency Use Authorization and Antibody Therapies

Facebook Twitter LinkedIn Email

A COVID-19 rapid response briefing with experts from the Infectious Diseases Society of America to discuss:

- What scientists know about antibody therapies
- Benefits and drawbacks to an emergency use authorization
- Scientific standards and transparency
- Questions from the media

Adarsh Bhimraj, MD, FIDSA—Cleveland, OH
Co-Chair—IDSA COVID-19 Treatment and Management Guidelines Expert Panel
Fellow—Infectious Diseases Society of America
Head of the Neurologic Infectious Diseases Section, Department of Infectious Diseases, Cleveland Clinic
Associate Staff Physician, Department of Infectious Diseases, Cleveland Clinic

Helen Boucher, MD, FIDSA—Boston, MA
Member, Board of Directors—Infectious Diseases Society of America
Chief, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center
Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR)

Dana Wollins, DrPH, MGC (Moderator)
Vice President, Clinical Affairs & Practice Guidelines—Infectious Diseases Society of America

Latest Media

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.